ARUXF.US Acrux Limited

Healthcare Biotechnology USA Stocks
0.0060 USD
Close of Nov 14, 2026
0.0001 0.0300
Market cap
USD 3.67M
P/E
-
P/B
3.65x
ROE
-41.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is ARUXF.US undervalued?

Graham number

The Graham number of Acrux Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Acrux Limited fundamental analysis

No fundamental analysis for Acrux Limited yet.

Acrux Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Acrux Limited

Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia;…

Full company profile